The Autoimmunity Risk Variant LYP-W620 Cooperates with CSK in the Regulation of TCR Signaling

PLoS ONE

Volumn 8, Issue 1, 2013, Pages

  de la Puerta, María Luisa ^a   Trinidad, Antonio G ^a   Rodríguez, María del Carmen ^a   de Pereda, José María ^b   Sánchez Crespo, Mariano ^a   Bayón, Yolanda ^a   Alonso, Andrés ^a  

^a UNIVERSITY OF VALLADOLID   (Spain)

^b UNIVERSITY OF SALAMANCA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

GLUTATHIONE TRANSFERASE; NON RECEPTOR PROTEIN TYROSINE PHOSPHATASE 22; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE CSK; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG;

ARTICLE; AUTOIMMUNITY; CELLULAR IMMUNITY; CONTROLLED STUDY; ENZYME BINDING; ENZYME REGULATION; ENZYME SUBSTRATE COMPLEX; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; MOLECULAR BIOLOGY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN DOMAIN; PROTEIN MOTIF; PROTEIN PROTEIN INTERACTION; SINGLE NUCLEOTIDE POLYMORPHISM; T LYMPHOCYTE;

AUTOIMMUNE DISEASES; AUTOIMMUNITY; ELECTROPHORESIS, POLYACRYLAMIDE GEL; FLOW CYTOMETRY; HEK293 CELLS; HUMANS; IMMUNOHISTOCHEMISTRY; JURKAT CELLS; MODELS, MOLECULAR; PHOSPHORYLATION; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEIN BINDING; PROTEIN TYROSINE PHOSPHATASES; RECEPTORS, ANTIGEN, T-CELL; SIGNAL TRANSDUCTION; SRC-FAMILY KINASES;

EID: 84872832172     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0054569     Document Type: Article

References (40)

1. Alonso A, Sasin J, Bottini N, Friedberg I, Friedberg I, et al. (2004) Protein tyrosine phosphatases in the human genome. Cell 117: 699-711.
2. Pao LI, Badour K, Siminovitch KA, Neel BG, (2007) Nonreceptor protein-tyrosine phosphatases in immune cell signaling. Annu Rev Immunol 25: 473-523.
3. Vang T, Miletic AV, Bottini N, Mustelin T, (2007) Protein tyrosine phosphatase PTPN22 in human autoimmunity. Autoimmunity 40: 453-461.
4. Wu J, Katrekar A, Honigberg LA, Smith AM, Conn MT, et al. (2006) Identification of substrates of human protein-tyrosine phosphatase PTPN22. J Biol Chem 281: 11002-11010.
5. Cohen S, Dadi H, Shaoul E, Sharfe N, Roifman CM, (1999) Cloning and characterization of a lymphoid-specific, inducible human protein tyrosine phosphatase, Lyp. Blood 93: 2013-2024.
6. Cloutier JF, Veillette A, (1999) Cooperative inhibition of T-cell antigen receptor signaling by a complex between a kinase and a phosphatase. J Exp Med 189: 111-121.
7. Cloutier JF, Chow LM, Veillette A, (1995) Requirement of the SH3 and SH2 domains for the inhibitory function of tyrosine protein kinase p50csk in T lymphocytes. Mol Cell Biol 15: 5937-5944.
8. Gregorieff A, Cloutier JF, Veillette A, (1998) Sequence requirements for association of protein-tyrosine phosphatase PEP with the Src homology 3 domain of inhibitory tyrosine protein kinase p50(csk). J Biol Chem 273: 13217-13222.
9. Bottini N, Musumeci L, Alonso A, Rahmouni S, Nika K, et al. (2004) A functional variant of lymphoid tyrosine phosphatase is associated with type I diabetes. Nat Genet 36: 337-338.
10. Begovich AB, Carlton VE, Honigberg LA, Schrodi SJ, Chokkalingam AP, et al. (2004) A missense single-nucleotide polymorphism in a gene encoding a protein tyrosine phosphatase (PTPN22) is associated with rheumatoid arthritis. Am J Hum Genet 75: 330-337.
11. Vang T, Miletic AV, Arimura Y, Tautz L, Rickert RC, et al. (2008) Protein tyrosine phosphatases in autoimmunity. Annu Rev Immunol 26: 29-55.
12. Cloutier JF, Veillette A, (1996) Association of inhibitory tyrosine protein kinase p50csk with protein tyrosine phosphatase PEP in T cells and other hemopoietic cells. Embo J 15: 4909-4918.
13. Vang T, Congia M, Macis MD, Musumeci L, Orru V, et al. (2005) Autoimmune-associated lymphoid tyrosine phosphatase is a gain-of-function variant. Nat Genet 37: 1317-1319.
14. Fiorillo E, Orru V, Stanford SM, Liu Y, Salek M, et al. (2010) Autoimmune-associated PTPN22 R620W variation reduces phosphorylation of lymphoid phosphatase on an inhibitory tyrosine residue. J Biol Chem 285: 26506-26518.
15. Zikherman J, Hermiston M, Steiner D, Hasegawa K, Chan A, et al. (2009) PTPN22 deficiency cooperates with the CD45 E613R allele to break tolerance on a non-autoimmune background. J Immunol 182: 4093-4106.
16. Zhang J, Zahir N, Jiang Q, Miliotis H, Heyraud S, et al. (2011) The autoimmune disease-associated PTPN22 variant promotes calpain-mediated Lyp/Pep degradation associated with lymphocyte and dendritic cell hyperresponsiveness. Nat Genet 43: 902-907.
17. Hasegawa K, Martin F, Huang G, Tumas D, Diehl L, et al. (2004) PEST domain-enriched tyrosine phosphatase (PEP) regulation of effector/memory T cells. Science 303: 685-689.
18. Kingston RE, Chen CW, Okayama H, Rose JK (2003) Transfection of DNA into eukaryotic cells. In: Ausubel FM, Brent R, Kingston RE, Moore DD, Seidman JG, et al. editors. Current Protocols in Molecular Biology. Hoboken, NJ: John Wiley and Sons Inc. 9.1.4-9.1.9.
19. Alonso A, Rahmouni S, Williams S, van Stipdonk M, Jaroszewski L, et al. (2003) Tyrosine phosphorylation of VHR phosphatase by ZAP-70. Nat Immunol 4: 44-48.
20. de la Puerta ML, Trinidad AG, del Carmen Rodriguez M, Bogetz J, Sanchez Crespo M, et al. (2009) Characterization of new substrates targeted by Yersinia tyrosine phosphatase YopH. PLOS One 4: e4431.
21. Davidson D, Cloutier JF, Gregorieff A, Veillette A, (1997) Inhibitory tyrosine protein kinase p50csk is associated with protein-tyrosine phosphatase PTP-PEST in hemopoietic and non-hemopoietic cells. J Biol Chem 272: 23455-23462.
22. Encinar JA, Fernandez-Ballester G, Sanchez IE, Hurtado-Gomez E, Stricher F, et al. (2009) ADAN: a database for prediction of protein-protein interaction of modular domains mediated by linear motifs. Bioinformatics 25: 2418-2424.
23. Ghose R, Shekhtman A, Goger MJ, Ji H, Cowburn D, (2001) A novel, specific interaction involving the Csk SH3 domain and its natural ligand. Nat Struct Biol 8: 998-1004.
24. Liu BA, Jablonowski K, Raina M, Arce M, Pawson T, et al. (2006) The human and mouse complement of SH2 domain proteins-establishing the boundaries of phosphotyrosine signaling. Mol Cell 22: 851-868.
25. Blom N, Gammeltoft S, Brunak S, (1999) Sequence and structure-based prediction of eukaryotic protein phosphorylation sites. J Mol Biol 294: 1351-1362.
26. Obenauer JC, Cantley LC, Yaffe MB, (2003) Scansite 2.0: Proteome-wide prediction of cell signaling interactions using short sequence motifs. Nucleic Acids Res 31: 3635-3641.
27. Vang T, Liu WH, Delacroix L, Wu S, Vasile S, et al. (2012) LYP inhibits T-cell activation when dissociated from CSK. Nat Chem Biol 8(5): 437-446.
28. Bottini N, Vang T, Cucca F, Mustelin T, (2006) Role of PTPN22 in type 1 diabetes and other autoimmune diseases. Semin Immunol 18: 207-213.
29. Wang B, Lemay S, Tsai S, Veillette A, (2001) SH2 domain-mediated interaction of inhibitory protein tyrosine kinase Csk with protein tyrosine phosphatase-HSCF. Mol Cell Biol 21: 1077-1088.
30. Howell BW, Cooper JA, (1994) Csk suppression of Src involves movement of Csk to sites of Src activity. Mol Cell Biol 14: 5402-5411.
31. Chow LM, Fournel M, Davidson D, Veillette A, (1993) Negative regulation of T-cell receptor signalling by tyrosine protein kinase p50csk. Nature 365: 156-160.
32. Lin X, Ayrapetov MK, Lee S, Parang K, Sun G, (2005) Probing the communication between the regulatory and catalytic domains of a protein tyrosine kinase, Csk. Biochemistry 44: 1561-1567.
33. Levinson NM, Seeliger MA, Cole PA, Kuriyan J, (2008) Structural basis for the recognition of c-Src by its inactivator Csk. Cell 134: 124-134.
34. Dobenecker MW, Schmedt C, Okada M, Tarakhovsky A, (2005) The ubiquitously expressed Csk adaptor protein Cbp is dispensable for embryogenesis and T-cell development and function. Mol Cell Biol 25: 10533-10542.
35. Xu S, Huo J, Tan JE, Lam KP, (2005) Cbp deficiency alters Csk localization in lipid rafts but does not affect T-cell development. Mol Cell Biol 25: 8486-8495.
36. Gregoire C, Simova S, Wang Y, Sansoni A, Richelme S, et al. (2007) Deletion of the LIME adaptor protein minimally affects T and B cell development and function. Eur J Immunol 37: 3259-3269.
37. Rieck M, Arechiga A, Onengut-Gumuscu S, Greenbaum C, Concannon P, et al. (2007) Genetic variation in PTPN22 corresponds to altered function of T and B lymphocytes. J Immunol 179: 4704-4710.
38. Aarnisalo J, Treszl A, Svec P, Marttila J, Oling V, et al. (2008) Reduced CD4+ T cell activation in children with type 1 diabetes carrying the PTPN22/Lyp 620Trp variant. J Autoimmun 31: 13-21.
39. Lefvert AK, Zhao Y, Ramanujam R, Yu S, Pirskanen R, et al. (2008) PTPN22 R620W promotes production of anti-AChR autoantibodies and IL-2 in myasthenia gravis. J Neuroimmunol 197: 110-113.
40. Davidson D, Veillette A, (2001) PTP-PEST, a scaffold protein tyrosine phosphatase, negatively regulates lymphocyte activation by targeting a unique set of substrates. Embo J 20: 3414-3426.